Literature DB >> 31132350

Highly sensitive chemiluminescence enzyme immunoassay for the quantification of carcinoembryonic antigen in the presence of an enhancer and a stabilizer.

Seung Sun Kim1, Yujung Lee2, Hyung Shik Shin3, Ji Hoon Lee4.   

Abstract

Using the advantages of phenol red, a signal enhancer, and bovine serum albumin (BSA), a stabilizer of horseradish peroxidase (HRP), added in HRP enzyme reaction of Amplex Red and H2O2, highly sensitive 1,1'-oxalyldiimidazole chemiluminescence enzyme immunoassay (ODI-CLEIA) was developed to rapidly quantify trace levels of carcinoembryonic antigen (CEA) in human serum. Phenol red acts as an enhancer in ODI-CLEIA while BSA supported rapid and stable activation of HRP. The CL emission of resorufin formed from the HRP enzyme reaction in the presence of BSA and phenol red was about 70-fold brighter than that in the absence of both materials. ODI-CLEIA in the presence of BSA (1.5 mg/ml).and phenol red (1 mM) was able to rapidly analyze CEA in human serum with the wide linear calibration curve (2.5-100 ng/ml). The limit of detection (LOD = 3σ/slope) of ODI-CLEIA was as low as 0.19 ng/ml. Additionally, it was confirmed that the accuracy, precision, and reproducibility of ODI-CLEIA in the presence of BSA and phenol red were good with the statistically acceptable error range.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  1,1′-oxalyldiimidazole chemiluminescence (ODI-CL); Carcinoembryonic antigen (CEA); Chemiluminescence enzyme immunoassay (CLEIA); Enhancer; Horseradish peroxidase (HRP); Phenol red derivatives

Year:  2019        PMID: 31132350     DOI: 10.1016/j.jim.2019.05.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  1 in total

1.  Utilizing dual carriers assisted by enzyme digestion chemiluminescence signal enhancement strategy simultaneously detect tumor markers CEA and AFP.

Authors:  Xiluan Yan; Kun Zhao; Yunting Yang; Aojun Qiu; Xinlei Zhang; Jie Liu; Chengyi Zha; Xi Mai; Fanrong Ai; Xiangjuan Zheng
Journal:  Anal Sci       Date:  2022-04-11       Impact factor: 2.081

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.